China–Costa Rica FTA – Origin Cumulation Pharmaceutical Products

Quelle: https://www.oecd.org/trade/fta-china-costa-rica.htm

The origin cumulation in the China-Costa Rica FTA allows pharmaceutical products manufactured in Costa Rica, under specified origin criteria, to be considered originating products and thus benefit from tariff preferences.

Related Terms

You might also be interested in these terms

CAFTA-DR – Origin Cumulation Pharmaceutical Products

CAFTA-DR – Origin cumulation refers to the mechanism under the Central America Free Trade Agreement – Dominican Republic that allows countries to appl...

Learn more

EFTA–Chile FTA – Origin Cumulation Pharmaceutical Products

The EFTA-Chile Free Trade Agreement allows for origin cumulation for pharmaceutical products, meaning that these products can benefit from the accumul...

Learn more

EFTA–China FTA – Origin Cumulation Pharmaceutical Products

Origin cumulation under the EFTA–China FTA refers to the regulation that allows materials and products from certain EFTA states and China to be aggreg...

Learn more

EFTA-Canada FTA – Origin Cumulation Pharmaceutical Products

Origin cumulation refers to the practice wherein the origin of goods in a trade agreement is determined such that products from the EFTA region and Ca...

Learn more

China–Costa Rica FTA – Origin Cumulation Ceramics

Origin cumulation under the China-Costa Rica Free Trade Agreement refers to the ability to use originating goods from member countries for duty-free i...

Learn more

China-Costa Rica FTA – Origin Cumulation Machinery

The China-Costa Rica Free Trade Agreement (FTA) allows for the accumulation of origin rules within the machinery sector between both countries, creati...

Learn more